Walking one hour per day and the derived neutrophil-to-lymphocyte ratio are associated with outcome in palliative second-line immunotherapy for patients with recurrent and/or metastatic squamous cell carcinoma of head and neck
Por:
Caballero-Borrego, M, Piedra, A, Gallego, O, López-Pousa, A, Castillo, P, Navarrete, P, Prat, A, Grau, JJ
Publicada:
1 nov 2024
Ahead of Print:
1 ago 2024
Resumen:
Objectives: To determine whether routinary walking activity and the derived neutrophil-tolymphocyte ratio are associated with outcomes in patients with recurrent and/or metastatic squamous cell carcinoma of head and neck. Methods: This multicenter retrospective cohort study included 64 patients diagnosed with recurrent and/or metastatic squamous cell carcinoma of head and neck and treated with immunotherapy (Programmed Death-1 and Programmed Death-ligand-1 proteins inhibitors) at two tertiary centers. We compared a group that performed uninterrupted physical activity for 1 h per day and controls who performed no activity. The derived neutrophil-to-lymphocyte ratio was calculated as follows: [neutrophils / (leukocytes-- neutrophils)]. Progression-free survival and overall survival were evaluated. Results: We included 28 (44%) and 36 (56%) patients in the activity and non-activity groups, respectively. Patient characteristics, treatment details, and tumor Programmed Death-ligand-1 expression were not associated with either progression-free survival or overall survival. Physical activity was an independent beneficial factor for progression-free survival (p p < 0.001) and overall survival (p p < 0.001). By contrast, a derived neutrophil-to-lymphocyte ratio <3.5 was an independent beneficial factor for overall survival (p p = 0.013), but not for progression-free survival (p p = 0.328). Conclusions: Walking one hour per day and having a high proportion of lymphocytes to neutrophiles (expressed as a low derived neutrophil-to-lymphocyte ratio) independently predict a better prognosis in patients with recurrent and/or metastatic squamous cell carcinoma of head and neck treated with immunotherapy. Level of evidence: III. (c) 2024 Associacao, Brasileira de Otorrinolaringologia e Cirurgia Cervico-Facial. Published by Elsevier Espana, S.L.U. This is an open access article under the CC BY-NC-ND license (http:// creativecommons.org/licenses/by-nc-nd/4.0/).
Filiaciones:
Caballero-Borrego, M:
Hosp Clin Barcelona, Otolaryngol Dept, Barcelona, Spain
Univ Barcelona, Dept Cirurgia & Especialitats Medicoquirurg, Fac Med & Ciencies Salut, Barcelona, Spain
Inst Invest Biomed Agusti Pi Sunyer IDIBAPS, Barcelona, Spain
Piedra, A:
Hosp Santa Creu & Sant Pau, Med Oncol Dept, Barcelona, Spain
Gallego, O:
Hosp Santa Creu & Sant Pau, Med Oncol Dept, Barcelona, Spain
López-Pousa, A:
Hosp Santa Creu & Sant Pau, Med Oncol Dept, Barcelona, Spain
Castillo, P:
Hosp Clin Barcelona, Pathol Dept, Barcelona, Spain
Navarrete, P:
Univ Barcelona, Dept Med, Fac Med & Ciencies Salut, Barcelona, Spain
Prat, A:
Hosp Santa Creu & Sant Pau, Pathol Dept, Barcelona, Spain
Grau, JJ:
Hosp Clin Barcelona, Med Oncol Dept, Barcelona, Spain
hybrid, Green Published
|